This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

Biotech columnist Adam Feuerstein answers readers' questions about health care.
9/3/15 6:23AM
The signal of activity Sage Therapeutics sees with SAGE-547 in essential tremor may turn out to be real or a mirage.
9/3/15 6:01AM
Among all U.S.-listed biotech stocks, regardless of market cap, only 68 companies managed to end August with higher stock prices, while 267 biotech stocks lost ground.
9/1/15 7:27AM
Acquiring Scioderm gives Amicus another late-stage orphan disease drug expected to have pivotal trial data in the first half of next year.
8/31/15 6:01AM
Approving both the Biomarin and Sarepta drugs for Duchenne muscular dystrophy is the most politically expedient decision the FDA can make.
8/27/15 12:45PM
Last night, I exchanged emails with a number of investors who run dedicated health care funds. I wanted to know how they navigated Monday's market selloff.
8/25/15 7:38AM
The iShares Nasdaq Biotechnology Index (IBB), the most closely followed biotech sector index, is down less than 1% after a deep plunge at Monday's open.
8/24/15 12:43PM
Enrollment of new patients into the DCVax-L study is suspended until the company "submits certain information from the trial for regulatory review," Northwest Bio said.
8/24/15 8:53AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
8/21/15 5:55AM
The slow commercial launch of Afrezza, MannKind's inhaled mealtime insulin, continues to be the root cause of the company's balance-sheet woes.
8/20/15 9:14AM
Speculative biotech stocks that were huge winners for healthcare investors earlier this year are now down significantly from their 52-week highs.
8/19/15 10:30AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
8/7/15 6:10AM
RBC Capital analyst Michael Yee offers seven reasons why Biomarin Pharmaceuticals will secure U.S. approval for drisapersen to treat Duchenne muscular dystrophy, a rare, genetic muscle-wasting disease.
8/4/15 11:25AM
Investors asking Intra-Cellular for a copy of the scientific poster needed to conduct proper due diligence on ITI-007 are told they can't have it.
7/31/15 9:36AM
The only saving grace is that no one, not even the most Kool-Aid-drinking MannKind supporter, is surprised by Afrezza's poor sales.
7/30/15 11:03AM
MannKind isn't at risk of shutting down imminently because of the death-spiral convert, but the company was forced into a weakened negotiating position because Afrezza is selling poorly.
7/29/15 10:33AM
Gilead Sciences will not be blamed for a cooling of the biotech bull market, if any such thing exists.
7/28/15 4:15PM
It's a day that ends in "day," which means cancer immunotherapy is dominating the biotech news.
7/28/15 10:23AM
Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.
7/27/15 12:42PM
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
7/27/15 10:30AM
After 34 years in existence, Xoma still can't develop a drug successfully on its own.
7/22/15 10:41AM
Lilly uses a new but contentious methodology to suggest treatment benefit from its experimental Alzheimer's drug.
7/22/15 7:00AM
Biotech investors, circle November 23 and 24 on your calendars. Use a thick black marker. This will be an epic event for biotech investors.
7/20/15 2:10PM
Exelixis plans to seek expanded approval for Cometriq to treat kidney cancer in early 2016.
7/20/15 7:01AM

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


Chart of I:DJI
DOW 16,398.25 +46.87 0.29%
S&P 500 1,957.04 +8.18 0.42%
NASDAQ 4,752.6150 +2.6360 0.06%
Top Rated Stocks Top Rated Funds Top Rated ETFs